Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Federal Trade Commission
Queensland Health
Healthtrust
Fuji
Cerilliant
Chubb
Daiichi Sankyo
Dow
Farmers Insurance

Generated: June 25, 2018

DrugPatentWatch Database Preview

Details for Patent: 4,803,081

« Back to Dashboard

Summary for Patent: 4,803,081
Title: New pharmaceutical preparations with extended release
Abstract:An extended release perparation of an active compound with very low solubility containing the active compound dissolved or dispersed in a semi-solid or liquid non-ionic solubilizer and whereby the amount by weight of the solubilizer is at least equal to the amount by weight of the active compound as well as a process for the preparation thereof.
Inventor(s): Falk; Karl-Erik L. (Lindome, SE), Hugosson; Sven M. (Kungsbacka, SE), Rosinski; Adam (Molndal, SE), Sjogren; John A. (Molnlycke, SE)
Assignee: Aktiebolaget Hassle (Molndal, SE)
Application Number:07/034,500
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 4,803,081
Patent Claim Types:
see list of patent claims
Formulation; Compound; Process;

Drugs Protected by US Patent 4,803,081

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 4,803,081

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Sweden8601624Apr 11, 1986

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cantor Fitzgerald
Mallinckrodt
Medtronic
Covington
Merck
UBS
Harvard Business School
Cerilliant
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.